<DOC>
	<DOCNO>NCT00053794</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . PURPOSE : Phase II trial study effectiveness perifosine treat patient metastatic locally advanced soft tissue sarcoma .</brief_summary>
	<brief_title>Perifosine Treating Patients With Metastatic Locally Advanced Soft Tissue Sarcoma</brief_title>
	<detailed_description>OBJECTIVES : - Determine efficacy perifosine , term response rate duration response , patient untreated metastatic locally advanced soft tissue sarcoma . - Determine toxicity drug patient . - Determine early progression rate patient treat drug . OUTLINE : This non-randomized , non-blinded , multicenter study . Patients receive load dose oral perifosine twice day 1 daily day 2-21 first course . For subsequent course , patient receive load dose oral perifosine day 1 daily day 2-21 . Courses repeat every 28 day absence disease progression unacceptable toxicity . Patients follow 1 month . Patients stable responsive disease follow every 3 month thereafter . PROJECTED ACCRUAL : A total 15-30 patient accrue study within 12-18 month .</detailed_description>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Endometrial Neoplasms</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm metastatic locally advanced soft tissue sarcoma incurable standard therapy , include follow type : Uterine sarcomas Mixed mesodermal Leiomyosarcoma Endometrial stromal sarcoma Alveolar soft part sarcoma Angiosarcoma/lymphangiosarcoma Fibrosarcoma Hemangiopericytoma Leiomyosarcoma Liposarcoma Malignant fibrous histiocytoma Neurogenic sarcoma Pleomorphic rhabdomyosarcoma Synovial sarcoma Unclassifiable sarcoma Undifferentiated sarcoma Excluded diseases include follow : Bone sarcoma ( e.g. , osteosarcoma , Ewing 's sarcoma , chondrosarcoma ) Embryonal rhabdomyosarcoma Carcinosarcoma Kaposi 's sarcoma Malignant mesothelioma Neuroblastoma Gastrointestinal stromal tumor At least 1 unidimensionally measurable site disease ( outside previously irradiated area ) define : At least 20 mm xray physical exam At least 10 mm spiral CT scan At least 20 mm nonspiral CT scan NOTE : Bone lesion consider measurable NOTE : Patients whose sole site disease within previously irradiate area allow evidence progression new lesion irradiate field No known brain metastasis PATIENT CHARACTERISTICS : Age 18 Performance status ECOG 02 Life expectancy At least 12 week Hematopoietic Absolute granulocyte count least 1,500/mm^3 Platelet count least 100,000/mm^3 Hepatic Bilirubin great upper limit normal ( ULN ) AST great 2.5 time ULN Renal Creatinine great ULN Cardiovascular No symptomatic congestive heart failure No unstable angina pectoris No cardiac arrhythmia Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No prior allergic reaction attribute compound similar chemical biological composition perifosine No malignancy within past 5 year except adequately treat nonmelanoma skin cancer curatively treat carcinoma situ cervix No active ongoing infection No psychiatric illness social situation would limit compliance study requirement No concurrent uncontrolled illness PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy No prior systemic chemotherapy metastatic locally advanced disease At least 6 month since prior adjuvant chemotherapy No concurrent cytotoxic chemotherapy Endocrine therapy Not specify Radiotherapy See Disease Characteristics At least 4 week since prior radiotherapy ( except lowdose , nonmyelosuppressive radiotherapy ) No concurrent radiotherapy sole site measurable disease progressively symptomatic disease Surgery At least 4 week since prior major surgery Other No concurrent anticancer therapy investigational agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2010</verification_date>
	<keyword>adult alveolar soft-part sarcoma</keyword>
	<keyword>adult angiosarcoma</keyword>
	<keyword>adult fibrosarcoma</keyword>
	<keyword>adult leiomyosarcoma</keyword>
	<keyword>adult liposarcoma</keyword>
	<keyword>adult synovial sarcoma</keyword>
	<keyword>endometrial stromal sarcoma</keyword>
	<keyword>uterine leiomyosarcoma</keyword>
	<keyword>adult malignant hemangiopericytoma</keyword>
	<keyword>stage III adult soft tissue sarcoma</keyword>
	<keyword>stage III uterine sarcoma</keyword>
	<keyword>stage IV uterine sarcoma</keyword>
	<keyword>recurrent adult soft tissue sarcoma</keyword>
	<keyword>recurrent uterine sarcoma</keyword>
	<keyword>adult malignant fibrous histiocytoma</keyword>
	<keyword>adult neurofibrosarcoma</keyword>
	<keyword>adult rhabdomyosarcoma</keyword>
	<keyword>stage IV adult soft tissue sarcoma</keyword>
</DOC>